BTK-activated signaling regulates PDAC tumorigenesis.

Slides:

Advertisements

Similar presentations

Synergistic antitumor effect of anti-CD40/CpG and 14

Advertisements

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

AG-221 induces the differentiation of IDH2R140Q blasts along myeloid lineages in primary human AML xenograft models. AG-221 induces the differentiation.

Sunitinib plus rMVA–CEA–TRICOM vaccine decreased tumor burden and increased intratumoral infiltration of T lymphocytes in the MC38-CEA colon carcinoma.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis in tumors. Depletion of T cells, in particular CD8+ T cells, significantly.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

In vivo efficacy of gemcitabine and MK-1775.

by Adrienne Sallets, Sophie Robinson, Adel Kardosh, and Ronald Levy

STAT3 regulates IgE class switching in a Th2-type response.

Fig. 5 Local gel scaffold for T cell memory response.

Leukocytes in human PDAC

TANs mediate obesity-induced tumor progression and aggravated desmoplasia. TANs mediate obesity-induced tumor progression and aggravated desmoplasia. A,

CXCR5 expression accelerates Eμ-Tcl1 leukemogenesis and is indispensable for tumor cell recruitment to lymphoid B-cell follicles. CXCR5 expression accelerates.

Effect of antiangiogenic TKIs and rMVA–CEA–TRICOM vaccine on tumor compactness, tight junctions, and intratumoral pressure in the MC38-CEA model. Effect.

mpJX-594 effects on tumor burden and leukocyte influx.

Pharmacologic inhibitors of PI3Kγ suppress PDAC growth and metastasis.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Socs1 KD tumors exhibit a more T cell–inflamed phenotype and increased CD8+ T cell activation. Socs1 KD tumors exhibit a more T cell–inflamed phenotype.

Fig. 5 A competent Fc is required for the antitumor immune response.

PTX in combination with PLX397 induces antitumor T-cell response.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Gene expression changes associated with response to combination CPI-444 and anti–PD-L1 treatment in MC38 tumors. Gene expression changes associated with.

Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

Fig. 2 In situ vaccination of CpG in combination with anti-OX40 antibody cures established local and distant tumors. In situ vaccination of CpG in combination.

The contributions of anti-Ad antibody and T-cell responses to viral clearance in tumor and antitumor efficacy of Ad5 therapy. The contributions of anti-Ad.

CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition.

E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective breast tumors. E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective.

Conversion of CD11bhighCD27high NK cells into MDSCs leads to CD11bhighCD27high and CD11bhighCD27low NK cell reduction. Conversion of CD11bhighCD27high.

Antitumor activity of KM100+5 μmol/L MTX treatment in the presence or absence of CD8+ T cells in BALB-neuT mice bearing subcutaneous tumors of TUBO cells.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

5FU-induced specific activation of CD8+ T cells.

CD4+ and CD8+ TILs express surface CD137.

Orthotopic PDAC growth is regulated by B cells and FcRγ-positive myeloid cells. Orthotopic PDAC growth is regulated by B cells and FcRγ-positive myeloid.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

FcRγ signaling regulates BTK activation and mediates PDAC growth.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

CD4+ cells are required to generate protective immunity against the MT-HA tumor in HA104 mice. CD4+ cells are required to generate protective immunity.

DAC treatment alters immune cell composition and enhances cytokine production in the peritoneal lavage. DAC treatment alters immune cell composition and.

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

Anti-SEMA4D antibody regulates immune-cell infiltration and inhibits growth of Tubo.A5 orthotopic mammary carcinoma. Anti-SEMA4D antibody regulates immune-cell.

CPI-444 enhances T-cell activation in MC38 tumors.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

The PI3Kβ inhibitor enhances the antitumor activity of T cell–mediated immunotherapy in mice bearing PTEN loss tumors. The PI3Kβ inhibitor enhances the.

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

PDL192 and inhibit the growth of xenograft tumors.

Leukocyte populations in normal and neoplastic breast tissues.

GCS-100 selectively kills KRAS-addicted lung tumors.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

Ex vivo profiling of PD-1 blockade using MDOTS

BH3-targeted inhibitors drive specific resistance in human cell lines, which can be overcome with alternating or combining inhibitors. BH3-targeted inhibitors.

Lnc-C/EBPβ negatively regulates immune-suppressive function of MDSCs in vivo. Lnc-C/EBPβ negatively regulates immune-suppressive function of MDSCs in vivo.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

CD38 regulates tumor growth and metastasis by adenosine-mediated CD8+ T-cell suppression. CD38 regulates tumor growth and metastasis by adenosine-mediated.

Bezafibrate increases the number of effector CTLs by enhancing their survival capacity and proliferation. Bezafibrate increases the number of effector.

Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo.

Presentation transcript:

BTK-activated signaling regulates PDAC tumorigenesis. BTK-activated signaling regulates PDAC tumorigenesis. A, schemas for therapeutic administration of PCI-32765 (in drinking water [0.16% w/v]) beginning on day 14 after implantation and gemcitabine (Gem; 15 mg/kg, i.v., beginning on day 18) to late-stage PDAC tumor–bearing mice. 500 μg depleting αCD8 mAb antibody administered i.p. on days 15, 20, and 25. Cross signifies end point or death. B, percentage change in Ink4 2.2 (left) or p53 2.1.1 (right) tumor size from days 14 to 27 after implantation measured by ultrasonography and assessed following treatment with vehicle (−), PCI-32765, or Gem, and combinations as indicated. For Ink4 2.2, data from 3 independent experiments are shown, reflective of 5 independent experiments. For p53 2.1.1, data from one experiment are shown and are representative of 2 independent experiments. C, CD45+ leukocyte frequency from end-stage tumors as a percentage of total viable cells determined by FACS analysis of single-cell suspensions of tumors from treatment groups indicated. Data from 2 independent experiments are shown and are representative of 5 independent studies. D, representative photomicrographs showing immune-detection of αSMA in mice bearing end-stage Ink4 2.2 PDAC tumors treated as shown. Scale bars, 100 μm. E, percentage of granzyme B-positive (GnzB) cells of CD3+CD8+ cells as determined by FACS of end-stage Ink4 2.2 PDAC tumors treated as shown. Data from 2 independent experiments are shown and are representative of 4 independent studies. F, percentage of IFNγ+CD8+ T cells of CD3+CD8+ cells as determined by intracellular FACS assessment of ex vivo–stimulated Ink4 2.2 PDAC tumors harvested from mice at day 23 after implant. Data from 2 independent experiments are shown. G, fold change of percent of CD107a+CD8+ T cells of CD3+CD8+ cells analyzed by FACS of Ink4 2.2 PDAC tumors harvested from mice at day 23 after implant. Data from 2 independent experiments are shown. H, FACS analysis of Ink4 2.2 tumors from day 23 time points for percentages of PD-1+EOMES+ populations of CD3+CD8+ T cells. Data from 2 independent experiments are shown. Statistical significance was determined using the Student t test or one-way ANOVA when analyzing more than two groups. I, percentage change in Ink4 2.2 tumor size from days 14 to 27 after implantation measured by ultrasonography and assessed following treatment with vehicle (−), PCI-32765, or Gem, and combinations in mice also administered depleting monoclonal antibodies for CD8+ (αCD8) T cells as indicated. Data from 2 independent experiments are shown. *, P < 0.05; **, P < 0.01; ***, P < 0.001. For B–C and E–G and I, each data point reflects an individual tumor, with statistical means shown. Andrew J. Gunderson et al. Cancer Discov 2016;6:270-285 ©2016 by American Association for Cancer Research